Search Results - "Seo, Mikyung Kelly"

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer by Seo, Mikyung Kelly, Cairns, John

    Published in PloS one (26-09-2018)
    “…Recent advances in targeted therapies have raised expectations that the clinical application of biomarkers would improve patient's health outcomes and…”
    Get full text
    Journal Article
  2. 2

    How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review by Seo, Mikyung Kelly, Cairns, John

    Published in BMC cancer (01-09-2021)
    “…Abstract Background Despite the increasing economic assessment of biomarker-guided therapies, no clear agreement exists whether existing methods are sufficient…”
    Get full text
    Journal Article
  3. 3

    Has the development of cancer biomarkers to guide treatment improved health outcomes? by D′Avó Luís, Ana Beatriz, Seo, Mikyung Kelly

    Published in The European journal of health economics (01-07-2021)
    “…During the last decade, testing the patient’s biomarker status prior to the administration of corresponding co-dependent therapies has been emerging in…”
    Get full text
    Journal Article
  4. 4

    A Practical Guide to Modeling and Conducting a Cost-Effectiveness Analysis of Companion Biomarker Tests for Targeted Therapies Using R: Tutorial Paper by Seo, Mikyung Kelly, Strong, Mark

    Published in PharmacoEconomics (01-12-2021)
    “…Despite the increasing number of potential biomarkers identified in laboratories and reported in much literature, the adoption of biomarkers routinely…”
    Get full text
    Journal Article
  5. 5

    Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective? by Kenseth, Anna, Kantorova, Dominika, Seo, Mikyung Kelly, Aas, Eline, Cairns, John, Kerr, David, Askautrud, Hanne, Jacobsen, Jørn Evert

    Published in PharmacoEconomics (01-06-2024)
    “…Objectives Accurate risk stratification of patients with stage II and III colorectal cancer (CRC) prior to treatment selection enables limited health resources…”
    Get full text
    Journal Article
  6. 6

    The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE’s New Methods Manual by Angelis, Aris, Harker, Martin, Cairns, John, Seo, Mikyung Kelly, Legood, Rosa, Miners, Alec, Wiseman, Virginia, Chalkidou, Kalipso, Grieve, Richard, Briggs, Andrew

    Published in Value in health (01-10-2023)
    “…The National Institute for Health and Care Excellence (NICE) recently completed a review of its methods for health technology assessment, involving a 2-stage…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9

    HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective? by Seo, Mikyung Kelly, Straume, Oddbjørn, Akslen, Lars A., Cairns, John

    Published in PharmacoEconomics - open (01-09-2020)
    “…Background Despite the extensive use of bevacizumab in a range of oncology indications, the US FDA revoked its approval for breast cancers, and multiple…”
    Get full text
    Journal Article
  10. 10

    Cost-effectiveness analysis of vaccinating children in Malawi with RTS,S vaccines in comparison with long-lasting insecticide-treated nets by Seo, Mikyung Kelly, Baker, Peter, Ngo, Karen Ngoc-Lan

    Published in Malaria journal (24-02-2014)
    “…New RTS,S malaria vaccines may soon be licensed, yet its cost-effectiveness is unknown. Before the widespread introduction of RTS,S vaccines,…”
    Get full text
    Journal Article